Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Antibodies
Filter     Order     Display # 
Date Item Title
02 Nov 2007 Seattle Genetics Initiates SGN-40 Clinical Trial in Combination with Revlimid for Multiple Myeloma
01 Nov 2007 Seattle Genetics and MedImmune Expand Antibody-Drug Conjugate Collaboration
30 Oct 2007 Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
29 Oct 2007 Peptech successfully completes Phase I trial for PN0621
26 Oct 2007 Novel Alternative Approach to Inhibiting Insulin Growth Factor (IGF) May Provide New Treatment for Breast Cancer and Other Cancers
26 Oct 2007 Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
25 Oct 2007 Human Genome Sciences presents new data showing anti-tumor activity and safety of trail receptor antibodies in combination with chemotherapy
25 Oct 2007 Milatuzumab Showed Promising Therapeutic Effects Alone and Combined With CD20 Antibody in Preclinical Studies
25 Oct 2007 ImmunoGen, Inc. Reports New Clinical and Preclinical Data at AACR-NCI-EORTC
25 Oct 2007 Seattle Genetics Reports Preclinical Data on SGN-40 and an Anti-CD19 Antibody-Drug Conjugate
25 Oct 2007 CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
24 Oct 2007 ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
24 Oct 2007 Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
24 Oct 2007 GlaxoSmithKline And Tolerx Form Worldwide Collaboration For Development And Commercialization Of Novel Medication
24 Oct 2007 Phase I results announced for R1507 from Genmab's Collaboration with Roche
20 Oct 2007 BioWa Announces Licensing of POTELLIGENT(R) Technology by GlaxoSmithKline (GSK)
19 Oct 2007 Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
18 Oct 2007 Lilly and MacroGenics Announce Licensing and Collaboration Agreement
18 Oct 2007 Abbott Scientists Create One Molecule With Two Antibody Functions
17 Oct 2007 Merck Serono Announces Joint Agreement with ImClone and Bristol-Myers Squibb for Erbitux in Japan
17 Oct 2007 ImmunoGen, Inc. Earns Milestone with Start of SAR3419 Clinical Testing
17 Oct 2007 Scientists Show Monoclonal Antibody Leads to Repair of Myelin Sheath in Laboratory Study of Multiple Sclerosis
16 Oct 2007 Bradmer provides Phase III Neuradiab trial update and guidance
16 Oct 2007 Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis
16 Oct 2007 Medimmune and Crucell announce collaboration to develop new antibodies for the treatment and prevention of hospital-acquired bacterial infection
12 Oct 2007 WILEX' second product enters Phase III trial: IND approval from FDA for registration trial with CA9-SCAN
12 Oct 2007 Genmab Amends HuMax-CD4 Pivotal Study in CTCL
12 Oct 2007 Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
09 Oct 2007 MorphoSys Enters Therapeutic Research Collaboration on Novel Target Molecule with Genesis Research
06 Oct 2007 New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrine's Anti-PS Technology Platform
06 Oct 2007 Argenes initiates Phase I clinical study of ARG098 (anti-Fas IgM monoclonal antibody), a novel therapeutics for rheumatoid arthritis, in Europe
05 Oct 2007 ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis
04 Oct 2007 Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
03 Oct 2007 Crucell presents Phase I results rabies antibody cocktail showing safety and ability to protect
03 Oct 2007 Roche Files CTA for Third Genmab Antibody
03 Oct 2007 Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports Use as a Single Agent in Patients with Advanced Colorectal Cancer
02 Oct 2007 Regeneron Announces Positive Primary Endpoint Results from a Phase 2 Study of VEGF Trap-Eye in Age-related Macular Degeneration
01 Oct 2007 Preclinical Study Published in Nature Medicine Shows Anti-LINGO-1 AntibodyPromotes Remyelination
28 Sep 2007 Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
28 Sep 2007 Crucell discovers human monoclonal antibodies for the prevention and treatment of the avian flu virus
27 Sep 2007 Herceptin eradicates tumours and may reduce the need for mastectomies in women with inflammatory HER2-positive breast cancer – one of the most aggressive and fastest growing forms of the disease
27 Sep 2007 Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
26 Sep 2007 Biotie has started the first phase I clinical trial with its fully human VAP-1 monoclonal antibody as it has received the final regulatory approval to do so
26 Sep 2007 Abbott and Eisai submit application for adalimumab, the only fully human monoclonal anti-TNFalpha antibody, to treat psoriasis
26 Sep 2007 New Biomarker Data Links KRAS Gene to Vectibix(TM) Clinical Response
22 Sep 2007 Vectibix(TM) (panitumumab) Receives Positive Opinion for Marketing Authorization in the European Union
21 Sep 2007 FDA Approves Expanded Labeling for Campath® to Include First-line Treatment for Leading Form of Adult Leukemia
21 Sep 2007 ImClone Systems Expands IMC-A12 Development with Ten New Planned Clinical Trials
21 Sep 2007 Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
19 Sep 2007 LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 Therapies
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 351 - 400 of 1053

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Emerging Diabetes Drugs

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics